Business Context and Reporting Period
Company: Advanced Biomed Inc. (ADVB)
Filing Type: Form 8-K (Current Report)
Date of Report: February 20, 2026
Reporting Period: The filing reports on a corporate action effective February 20, 2026, regarding a reverse stock split approved on February 3, 2026.
Key Financial Metrics
This filing is a current report regarding a capital structure change and does not contain financial performance data. The following metrics are not provided in this document:
- Revenue, profit, and cash flow
- Operating margins
- Debt levels and liquidity positions
Material Changes
The primary material change reported is a 1-for-20 reverse stock split of the Company's common stock.
- Effective Date: February 20, 2026 (at the open of trading on The Nasdaq Capital Market).
- Mechanism: Every 20 shares of issued and outstanding Common Stock were automatically converted into 1 share.
- Par Value: Remained unchanged at $0.001 per share.
- Authorized Shares: No change to the total number of authorized shares.
- Fractional Shares: No fractional shares were issued; holders entitled to fractions received a rounded-up whole share. No cash was paid in lieu of fractional shares.
- Trading Symbol: Remains "ADVB" on The Nasdaq Capital Market.
- CUSIP: Updated to 00752P203.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors related to financial performance. The document focuses solely on the procedural details of the amendment to the Articles of Incorporation and the execution of the reverse stock split.
Investor Verification Checklist
- Verify the new CUSIP number (00752P203) with your broker to ensure proper account adjustment.
- Confirm the number of shares held post-split (original holdings divided by 20, rounded up to the nearest whole share).
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for any additional legal stipulations.
- Check the press release (Exhibit 99.1) for any supplementary details regarding the rationale for the split.